Alzheimer's-focused M3 Biotechnology rebrands as Athira Pharma

boardroom
The former M3 had received assistance for its early clinical trials from the Alzheimer’s Drug Discovery Foundation. Going forward, Athira’s phase 2 study will be supported in part by the Alzheimer’s Association. (Pixabay)

Seattle-based M3 Biotechnology has changed its name to Athira Pharma, derived from the Arabic word meaning “a force” or “an energy,” which the company says aligns with its focus on developing regenerative therapies for Alzheimer’s, Parkinson’s and multiple sclerosis.

Athira aims to restore the lost neural connections in the brain, or spur the growth of new ones, starting with its small molecule candidate NDX-1017—currently undergoing its first-in-human trial in patients with Alzheimer’s disease, dementia or mild cognitive impairments in the U.S. and France.

The company plans to launch a phase 2 proof-of-concept study before the end of 2019 to examine the drug’s long-term safety and other exploratory endpoints. Meanwhile, preliminary results from the ongoing, placebo-controlled phase 1 study will be presented at a scientific conference midyear, Athira said.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

"Throughout our development efforts, we are maintaining a constant awareness of the individuals we hope to positively impact with our treatments," President and CEO Leen Kawas said in a statement. "We believe we need to work together to implement trials that are people-focused and strive to make treatments that are impactful and accessible."

RELATED: Biogen hit by 'transformative failure' as it cans aducanumab tests

Early preclinical studies showed the drug was able to build new neural connections in rats—a different approach compared to therapies targeting amyloid plaque buildups in the brain. Those attempts have seen several high-profile failures over the years, most recently with Biogen and Eisai’s phase 3 aducanumab program.

RELATED: Bezos joins Gates-backed Alzheimer's diagnostics accelerator with new focus on digital biomarkers

The former M3 had received assistance for its early clinical trials from the Alzheimer’s Drug Discovery Foundation—going forward, Athira’s phase 2 trials will be supported in part by the Alzheimer’s Association under its Part the Cloud grant program and an initiative aimed at reversing brain cell degeneration at its earliest stages.

Suggested Articles

California is halting its expansion, citing costs, despite seeing record-setting spikes in new infections and increases in hospitalizations.

Antivirals from Roche, Bristol Myers Squibb, Viiv and Gilead, or modified versions of them, could prove effective against COVID-19, researchers said.

The Canadian devicemaker Kardium has received European approval for its spherical heart ablation system designed to treat atrial fibrillation.